1. Home
  2. ASST vs TRAX Comparison

ASST vs TRAX Comparison

Compare ASST & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Asset Entities Inc. Class B

ASST

Asset Entities Inc. Class B

SELL

Current Price

$29.86

Market Cap

1.0B

Sector

Technology

ML Signal

SELL

TRAX

First Tracks Biotherapeutics Inc. Ordinary Shares

N/A

Current Price

$32.00

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASST
TRAX
Founded
2020
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2022
2026

Fundamental Metrics

Financial Performance
Metric
ASST
TRAX
Price
$29.86
$32.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
12
Target Price
$33.20
★ $70.00
AVG Volume (30 Days)
★ 7.3M
567.8K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 82.56
N/A
EPS
N/A
★ N/A
Revenue
★ $633,489.00
N/A
Revenue This Year
$107.15
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 128.67
N/A
52 Week Low
$0.49
$15.69
52 Week High
$31.95
$49.91

Technical Indicators

Market Signals
Indicator
ASST
TRAX
Relative Strength Index (RSI) 66.05 33.89
Support Level $10.68 $15.69
Resistance Level $31.95 $48.94
Average True Range (ATR) 1.57 2.63
MACD -0.40 -0.56
Stochastic Oscillator 57.06 7.66

Price Performance

Historical Comparison
ASST
TRAX

About ASST Asset Entities Inc. Class B

Strive Inc is a structured finance company and institutional asset manager focused on disciplined capital allocation and long term value creation. The company has adopted bitcoin as its hurdle rate for capital deployment because of its fiduciary duty to maximize long-term value for stockholders, and compounding purchasing power over time. It operates in two reportable operating segments: the Asset Management segment, which provides investment advisory services and the Corporate & Other segment, which includes the company's bitcoin treasury operations. The majority of the revenue is derived from the Asset Management segment.

About TRAX First Tracks Biotherapeutics Inc. Ordinary Shares

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

Share on Social Networks: